|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-29
|
|
pubmed:abstractText |
In Radiation Therapy Oncology Group (RTOG) trial 92-02, after men received neoadjuvant hormone cytoreduction and radiotherapy for locally advanced prostate carcinoma, they were randomized to receive either 2 years of long-term androgen-deprivation (LTAD) or no further treatment (short-term androgen-deprivation [STAD]). The specific objective of the current study was to determine whether LTAD was a cost-effective treatment for patients with locally advanced prostate carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2005 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
51-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16323171-Adenocarcinoma,
pubmed-meshheading:16323171-Androgen Antagonists,
pubmed-meshheading:16323171-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16323171-Combined Modality Therapy,
pubmed-meshheading:16323171-Cost-Benefit Analysis,
pubmed-meshheading:16323171-Flutamide,
pubmed-meshheading:16323171-Goserelin,
pubmed-meshheading:16323171-Humans,
pubmed-meshheading:16323171-Male,
pubmed-meshheading:16323171-Markov Chains,
pubmed-meshheading:16323171-Monte Carlo Method,
pubmed-meshheading:16323171-Neoadjuvant Therapy,
pubmed-meshheading:16323171-Prostatic Neoplasms,
pubmed-meshheading:16323171-Quality-Adjusted Life Years,
pubmed-meshheading:16323171-Radiotherapy, Conformal,
pubmed-meshheading:16323171-Randomized Controlled Trials as Topic
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. andre.konski@fccc.edu
|
|
pubmed:publicationType |
Journal Article
|
